Logo image of ONVO

ORGANOVO HOLDINGS INC (ONVO) Stock Fundamental Analysis

NASDAQ:ONVO - Nasdaq - US68620A2033 - Common Stock - Currency: USD

1.72  +0.06 (+3.61%)

After market: 1.69 -0.03 (-1.74%)

Fundamental Rating

2

Taking everything into account, ONVO scores 2 out of 10 in our fundamental rating. ONVO was compared to 568 industry peers in the Biotechnology industry. ONVO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ONVO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ONVO had negative earnings in the past year.
ONVO had a negative operating cash flow in the past year.
ONVO had negative earnings in each of the past 5 years.
In the past 5 years ONVO always reported negative operating cash flow.
ONVO Yearly Net Income VS EBIT VS OCF VS FCFONVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ONVO's Return On Assets of -322.19% is on the low side compared to the rest of the industry. ONVO is outperformed by 95.07% of its industry peers.
ONVO has a worse Return On Equity (-3402.47%) than 84.51% of its industry peers.
Industry RankSector Rank
ROA -322.19%
ROE -3402.47%
ROIC N/A
ROA(3y)-116.81%
ROA(5y)-91.68%
ROE(3y)-185.97%
ROE(5y)-134.22%
ROIC(3y)N/A
ROIC(5y)N/A
ONVO Yearly ROA, ROE, ROICONVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONVO Yearly Profit, Operating, Gross MarginsONVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

4

2. Health

2.1 Basic Checks

ONVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ONVO has more shares outstanding
The number of shares outstanding for ONVO has been increased compared to 5 years ago.
There is no outstanding debt for ONVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ONVO Yearly Shares OutstandingONVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ONVO Yearly Total Debt VS Total AssetsONVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

ONVO has an Altman-Z score of -137.62. This is a bad value and indicates that ONVO is not financially healthy and even has some risk of bankruptcy.
ONVO has a worse Altman-Z score (-137.62) than 97.18% of its industry peers.
There is no outstanding debt for ONVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -137.62
ROIC/WACCN/A
WACC10.33%
ONVO Yearly LT Debt VS Equity VS FCFONVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

ONVO has a Current Ratio of 0.72. This is a bad value and indicates that ONVO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ONVO (0.72) is worse than 91.37% of its industry peers.
ONVO has a Quick Ratio of 0.72. This is a bad value and indicates that ONVO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ONVO (0.72) is worse than 91.20% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.72
ONVO Yearly Current Assets VS Current LiabilitesONVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

4

3. Growth

3.1 Past

ONVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.26%, which is quite impressive.
ONVO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -50.20%.
ONVO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -48.77% yearly.
EPS 1Y (TTM)60.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-473%
Revenue 1Y (TTM)-50.2%
Revenue growth 3YN/A
Revenue growth 5Y-48.77%
Sales Q2Q%380%

3.2 Future

The Earnings Per Share is expected to grow by 25.11% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 45.71% on average over the next years. This is a very strong growth
EPS Next Y96.31%
EPS Next 2Y40.15%
EPS Next 3Y25.11%
EPS Next 5YN/A
Revenue Next Year126.67%
Revenue Next 2Y63.71%
Revenue Next 3Y45.71%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ONVO Yearly Revenue VS EstimatesONVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M
ONVO Yearly EPS VS EstimatesONVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2021 2024 2025 2026 2027 -20 -40 -60 -80 -100

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONVO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONVO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONVO Price Earnings VS Forward Price EarningsONVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONVO Per share dataONVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as ONVO's earnings are expected to grow with 25.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.15%
EPS Next 3Y25.11%

0

5. Dividend

5.1 Amount

ONVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ORGANOVO HOLDINGS INC

NASDAQ:ONVO (4/17/2025, 8:00:02 PM)

After market: 1.69 -0.03 (-1.74%)

1.72

+0.06 (+3.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/bmo
Earnings (Next)N/A N/A
Inst Owners16.11%
Inst Owner Change0%
Ins Owners1.23%
Ins Owner Change0%
Market Cap2.92M
Analysts45.71
Price TargetN/A
Short Float %8.04%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.02%
Min EPS beat(2)10.83%
Max EPS beat(2)47.21%
EPS beat(4)4
Avg EPS beat(4)30.5%
Min EPS beat(4)10.83%
Max EPS beat(4)47.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-37.39%
Min Revenue beat(2)-46.52%
Max Revenue beat(2)-28.26%
Revenue beat(4)0
Avg Revenue beat(4)-38.8%
Min Revenue beat(4)-62.09%
Max Revenue beat(4)-18.3%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.97
P/FCF N/A
P/OCF N/A
P/B 8.03
P/tB 8.03
EV/EBITDA N/A
EPS(TTM)-4.49
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-5.95
FCFYN/A
OCF(TTM)-5.94
OCFYN/A
SpS0.07
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -322.19%
ROE -3402.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.81%
ROA(5y)-91.68%
ROE(3y)-185.97%
ROE(5y)-134.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.71%
Cap/Sales 10.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.72
Altman-Z -137.62
F-Score3
WACC10.33%
ROIC/WACCN/A
Cap/Depr(3y)148.6%
Cap/Depr(5y)294.16%
Cap/Sales(3y)57.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-473%
EPS Next Y96.31%
EPS Next 2Y40.15%
EPS Next 3Y25.11%
EPS Next 5YN/A
Revenue 1Y (TTM)-50.2%
Revenue growth 3YN/A
Revenue growth 5Y-48.77%
Sales Q2Q%380%
Revenue Next Year126.67%
Revenue Next 2Y63.71%
Revenue Next 3Y45.71%
Revenue Next 5YN/A
EBIT growth 1Y36.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.51%
OCF growth 3YN/A
OCF growth 5YN/A